Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density.

PURPOSE The goal in this study was to determine the incidence of subclinical neuropathy in treatment-naive patients with multiple myeloma (MM) with no history of peripheral neuropathy using quantitative sensory tests (QSTs) and its correlation with innervation density of the extremities using noninvasive laser reflectance confocal microscopy. PATIENTS AND METHODS QST results were collected for 27 patients with a diagnosis of MM and compared with data collected from 30 age- and sex-matched healthy volunteers. Skin temperature, sensorimotor function (grooved pegboard test), and detection thresholds for temperature, sharpness, and low-threshold mechanical stimuli (von Frey monofilaments and bumps detection test) were measured. Meissner's corpuscle (MC) density in the fingertips was assessed using in vivo laser reflectance confocal microscopy. RESULTS Patients showed a high incidence (> 80%) of ≥ one subclinical QST deficit. These included increased von Frey, bumps, and warmth detection thresholds as compared with healthy volunteers. Patients also showed increases in cold pain, sensorimotor deficits (grooved pegboard test), and higher overall neuropathy scores. MC density was significantly lower in patients than controls and showed significant inverse correlation with bumps detection threshold. CONCLUSION Patients with MM commonly present with sensory and sensorimotor deficits before undergoing treatment, and these deficits seem to result from disease-related decreases in peripheral innervation density.

[1]  C. Cleeland,et al.  Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.

[2]  C. Cleeland,et al.  Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy , 2012, Clinical Cancer Research.

[3]  P. Wen,et al.  Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012, Leukemia.

[4]  P. Dougherty,et al.  Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. , 2011, The journal of pain : official journal of the American Pain Society.

[5]  M. Nolano,et al.  A new device to quantify tactile sensation in neuropathy , 2011, Neurology.

[6]  P. Sonneveld,et al.  Dealing with neuropathy in plasma-cell dyscrasias. , 2010, Hematology. American Society of Hematology. Education Program.

[7]  J. Liao,et al.  Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. , 2010, Clinical lymphoma, myeloma & leukemia.

[8]  Heinz Ludwig,et al.  Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. , 2010, The Lancet. Oncology.

[9]  K. Anderson,et al.  Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  D. Esseltine,et al.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Lonial,et al.  Review of peripheral neuropathy in plasma cell disorders , 2008, Hematological oncology.

[12]  Christi Alessi-Fox,et al.  In vivo confocal microscopy of Meissner corpuscles as a measure of sensory neuropathy , 2007, Neurology.

[13]  R. Michelucci,et al.  Neuropathy in multiple myeloma treated with thalidomide , 2007, Neurology.

[14]  P. Dougherty,et al.  Quantitative sensory findings in patients with bortezomib-induced pain. , 2007, The journal of pain : official journal of the American Pain Society.

[15]  C. Lacroix,et al.  Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma , 2006, Neurology.

[16]  P. Dougherty,et al.  Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients , 2004, Pain.

[17]  E. Dees,et al.  The proteasome as a target for cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  R. Meyer,et al.  Secondary hyperalgesia persists in capsaicin desensitized skin , 2000, PAIN®.

[19]  A. Ropper,et al.  Neuropathies associated with paraproteinemia. , 1998, The New England journal of medicine.

[20]  R M Ruff,et al.  Gender- and Age-Specific Changes in Motor Speed and Eye-Hand Coordination in Adults: Normative Values for the Finger Tapping and Grooved Pegboard Tests , 1993, Perceptual and motor skills.

[21]  J. Vallat,et al.  Magnesium sulfate for AIP seizures , 1981, Neurology.

[22]  P. Dyck,et al.  The spectrum of peripheral neuropathy in myeloma , 1981, Neurology.

[23]  A. Silverstein Neurological complications of anticoagulation therapy: a neurologist's review. , 1979, Archives of internal medicine.

[24]  H. Hensel,et al.  Warm fiber activity in human skin nerves , 1975, Pflügers Archiv.

[25]  H. E. Torebjörk,et al.  Afferent C units responding to mechanical, thermal and chemical stimuli in human non-glabrous skin. , 1974, Acta physiologica Scandinavica.

[26]  H. Fruhstorfer,et al.  Dissociated loss of cold and warm sensibility during regional anaesthesia , 1974, Pflügers Archiv.

[27]  P J Dyck,et al.  A quantitative study of Meissner's corpuscles in man , 1966, Neurology.

[28]  A. Silverstein,et al.  NEUROLOGIC COMPLICATIONS OF MYELOMATOSIS. , 1963, Archives of neurology.

[29]  S. Hassenbusch,et al.  Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. , 2004, Journal of pain and symptom management.